Min Zhao, Lixing Wang, Xingyu Wang, Juan He, Kuai Yu, Dan Li
{"title":"Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.","authors":"Min Zhao, Lixing Wang, Xingyu Wang, Juan He, Kuai Yu, Dan Li","doi":"10.1177/03008916231221636","DOIUrl":null,"url":null,"abstract":"<p><p>The microenvironment of diffuse large B-cell lymphoma (DLBCL) is composed of various components, including immune cells and immune checkpoints, some of which have been correlated with the prognosis of DLBCL, but their results remain controversial. Therefore, we conducted a systematic review and meta-analysis to investigate the association between the microenvironment and prognosis in DLBCL. We searched PubMed, Web of Science, and EMBASE for relevant articles between 2001 and 2022. Twenty-five studies involving 4495 patients with DLBCL were included in the analysis. This meta-analysis confirmed that high densities of Foxp3+Tregs and PD-1+T cells are good indicators for overall survival (OS) in DLBCL, while high densities of programmed cell death protein ligand1(PD-L1)-positive expression cells and T-cell immunoglobulin-and mucin domain-3-containing molecule 3 (TIM-3)-positive expression tumor-infiltrating cells (TILs) play a contrary role in OS. Additionally, higher numbers of T-cell intracytoplasmic antigen-1(TIA-1)-positive expression T cells imply better OS and progression-free survival (PFS), while high numbers of lymphocyte activation gene(LAG)-positive expression TILs predict bad OS and PFS. Various non-tumoral cells in the microenvironment play important roles in the prognosis of DLBCL.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"227-240"},"PeriodicalIF":2.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916231221636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The microenvironment of diffuse large B-cell lymphoma (DLBCL) is composed of various components, including immune cells and immune checkpoints, some of which have been correlated with the prognosis of DLBCL, but their results remain controversial. Therefore, we conducted a systematic review and meta-analysis to investigate the association between the microenvironment and prognosis in DLBCL. We searched PubMed, Web of Science, and EMBASE for relevant articles between 2001 and 2022. Twenty-five studies involving 4495 patients with DLBCL were included in the analysis. This meta-analysis confirmed that high densities of Foxp3+Tregs and PD-1+T cells are good indicators for overall survival (OS) in DLBCL, while high densities of programmed cell death protein ligand1(PD-L1)-positive expression cells and T-cell immunoglobulin-and mucin domain-3-containing molecule 3 (TIM-3)-positive expression tumor-infiltrating cells (TILs) play a contrary role in OS. Additionally, higher numbers of T-cell intracytoplasmic antigen-1(TIA-1)-positive expression T cells imply better OS and progression-free survival (PFS), while high numbers of lymphocyte activation gene(LAG)-positive expression TILs predict bad OS and PFS. Various non-tumoral cells in the microenvironment play important roles in the prognosis of DLBCL.
弥漫大B细胞淋巴瘤(DLBCL)的微环境由多种成分组成,包括免疫细胞和免疫检查点,其中一些成分与DLBCL的预后相关,但其结果仍存在争议。因此,我们进行了一项系统综述和荟萃分析,研究微环境与 DLBCL 预后之间的关系。我们检索了2001年至2022年间在PubMed、Web of Science和EMBASE上发表的相关文章。分析共纳入了25项研究,涉及4495名DLBCL患者。这项荟萃分析证实,高密度的Foxp3+Tregs和PD-1+T细胞是DLBCL患者总生存(OS)的良好指标,而高密度的程序性细胞死亡蛋白配体1(PD-L1)阳性表达细胞和T细胞免疫球蛋白和粘蛋白结构域-3-含分子3(TIM-3)阳性表达的肿瘤浸润细胞(TILs)在OS中起着相反的作用。此外,T细胞胞浆内抗原-1(TIA-1)阳性表达的T细胞数量越多,预示着OS和无进展生存期(PFS)越好,而淋巴细胞活化基因(LAG)阳性表达的TIL数量越多,预示着OS和PFS越差。微环境中的各种非肿瘤细胞在DLBCL的预后中发挥着重要作用。
期刊介绍:
Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.